Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
(2019).
(2018).
Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin..
Clin Colorectal Cancer. 15(2), 164-9.
(2016).
(2015).
(2015).
(2015).
The impact of oxaliplatin-based chemotherapy for colorectal cancer on the autonomous nervous system..
Eur J Neurol. 21(12), 1471-7.
(2014). Effect of pigmentation on photodynamic therapy..
Lancet Oncol. 14(9), e339-40.
(2013).
(2013).
(2013). Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel..
PLoS One. 7(6), e37946.
(2012). Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study..
Cancer Chemother Pharmacol. 69(2), 477-84.
(2012). Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression..
Clin Breast Cancer. 12(3), 183-93.
(2012). Management of malignant pleural effusion by suicide gene therapy in advanced stage lung cancer: a case series and literature review..
Cancer Gene Ther. 19(9), 593-600.
(2012). Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial..
Breast Cancer Res Treat. 132(2), 609-19.
(2012).
(2012).
(2012). The effects of the intraperitoneal administration of oxaliplatin and 5-FU on the healing of colonic anastomoses: an experimental study..
Tech Coloproctol. 15 Suppl 1, S111-5.
(2011). Intraperitoneally administered irinotecan with 5-fluorouracil impair wound healing of colonic anastomoses in a rat model: an experimental study..
Tech Coloproctol. 15 Suppl 1, S121-5.
(2011).
(2011). Anal function and intersphincteric resection..
Dis Colon Rectum. 53(6), 958-9.
(2010). Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG)..
Crit Rev Oncol Hematol. 76(1), 61-70.
(2010). Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer..
Anticancer Res. 30(10), 4325-33.
(2010). XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis..
Curr Med Res Opin. 25(3), 797-805.
(2009).